| Literature DB >> 25534862 |
Reza Mostafavi Tabatabaee1, Mohammad R Rasouli1, Mitchell G Maltenfort1, Javad Parvizi1.
Abstract
Although recent guidelines suggest aspirin for venous thromboembolism (VTE) prophylaxis in low risk patients following total hip arthroplasty (THA) and total knee arthroplasty (TKA), there are no cost-effectiveness studies comparing aspirin and warfarin. In a Markov cohort cost-effectiveness analysis, we found that aspirin cost less and saved more quality-adjusted life-years (QALYs) than warfarin in all age groups. Cost per QALY gained by aspirin was $24,506.20 at age of 55 and $47,148.10 at the age of 85 following THA and $15,117.20 and $24,458.10 after TKA, which were greater than warfarin. In patients undergoing THA/TKA without prior VTE, aspirin is more cost-effective prophylactic agent than warfarin. Warfarin might be a better prophylaxis in TKA patients with high probability of VTE and very low probability of bleeding.Entities:
Keywords: aspirin; cost-effectiveness analysis; total joint arthroplasty; venous thromboembolism; warafarin
Mesh：
Substances：
Year: 2014 PMID： 25534862 DOI： 10.1016/j.arth.2014.08.018
Source DB: PubMed Journal: J Arthroplasty ISSN： 0883-5403 Impact factor: 4.757